<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">

 

7th LSX CEO Forum 

Wednesday 27th June 2018, CMS, Cannon Place, 78 Cannon St, London EC4N 6AF

DOWNLOAD THE PROSPECTUS
REQUEST AN INVITATION

Host and Partner

CMS CAMERON MCKENNA
 

ABOUT THE LSX CEO FORUM

  • The mission of the 7th LSX CEO Forum (formerly Biotech and Money CEO Forum) is to provide a unique, powerful and valuable space for the candid sharing of experience between the sector’s most senior executives so that they can leave with new ideas that will drive their businesses and the sector forward. It is an invitation only, exclusive hollow square forum where all participants are active discussants and have an equal voice. 
  • Limited to 25 CXOs and KOLs to ensure conversation is meaningful, it follows a strict Chatham House Rule policy focused on brainstorming solutions and delivering outcomes to the collective challenges of CxOs in the sector.

 


Agenda for the daY

 

13:30

ARRIVAL AND REFRESHMENTS

13:45

WELCOME REMARKS AND INTRODUCTIONS

14:00

 

 

 

 

CAPITAL MARKET PERSPECTIVE: EUROPEAN FUNDRAISING OUTLOOK

  • Where is the money and what is it following?
  • What do you need to do to raise capital successfully in Europe?
  • What are investors looking for now?

Robert Crowley, Director, KPMG

14:30

 

 

 

 

 

 

CASE STUDIES AND PEER REVIEW

Confirmed case studies and presentations:

  • Acacia Pharma– The Acacia story and its €40m Euronext IPO - Julian Gilbert, CEO, Acacia Pharma (Confirmed)
  • NeRRe & KaNDY Therapeutics – Demerger of KaNDY, Business Model Innovation and Value Creation - Mary Kerr, CEO, NeRRe (Confirmed)
  • The application of AI in drug discovery and development - Mark Swindells, COO, ExScientia (Confirmed)

Shortlisted case studies:

  • Prexton Therapeutics –  Acquisition by Lundbeck in EUR 905m deal - Francois Conquet (CEO) and Nicolas Marsault (CFO) (Invited)
  • C4XD - $294M addiction drug deal with Indivior - Clive Dix, CEO, C4XD (Invited)
  • Sosei – AZ immune-oncology collaboration - Malcolm Weir, Chief R&D Officer, Sosei (former CEO Heptares) (Invited)

16:00

REFRESHMENTS

16:15

 

 

 

INVESTOR Q&A AND ROUNDTABLE DISCUSSION

What are life science investors looking for today?

A Q&A with some of Europe’s leading life science investors:

  • Richard Penny, Fund Manager, Crux Asset Management (Confirmed)
  • Stephen Yang, CIO, Curam Capital (Confirmed)
  • Jonathan Tobin, Investment Director, Arix Bioscience Plc (Confirmed)

18:00

 

LSX CONNECT NETWORKING RECEPTION

Join our community for drinks and canapes, with an evening reception co-located with our LSX Connect Summer networking event. 

18:40

 

LSX CONNECT SUMMER AGENDA

Open to executives registered for the CEO forum.

REQUEST AN INVITATION

PREVIOUS ATTENDEES INCLUDE

PFIZER
CLINIGEN
reneuron.png
IMMUNOCORE
Abzena
Astex
CHRONOS THERAPEUTICS
CRESCENDO BIOLOGICS
Scancell
GW pharmaceuticals
OXFORD BIOMEDICA
HORIZON DISCOVERY
verona pharma plc
ixico
Merck_Sharp__Dohme.png
Mereo-BioPharma.png
Midatech
f2g
mission therapeutics
PsiOxus
redx-pharma
tiziana life sciences
valirx-logo
ergomed
LEGAL & GENERAL INVESTMENT MANAGEMENT
REX BIONICS
IMMUPHARMA

EVENT VENUE

Venue: CMS Cameron McKenna Offices
Address : Cannon Place

78 Cannon Street, London EC4N 6AF

Mail : info@biotechandmoney.com

Contact : +44 (0) 203 637 5908

 

CONTACT US

Address : Suite 132, The Business Design Centre, 52 Upper St, London N1 0QH

Mail : info@biotechandmoney.com

Contact : +44 (0) 203 637 5908